Delivery Order SPE2DB22D9353-SPE2DB25FX2DZ
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $20,091.18 by the Defense Logistics Agency (DLA) on September 8, 2025. The delivery order, which is not subject to a set-aside designation, calls for the supply of Nplate 500 microgram vials with an ultimate completion date of September 29, 2025. This award is issued under DMS Pharmaceutical Group's existing Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $6,697.06 by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Nplate 500 microgram vials. The contract does not utilize a set-aside designation and carries an ultimate completion date of September 3, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $6,697.06 by the Defense Logistics Agency (DLA) on August 25, 2025, for the supply of Nplate 500 microgram vials. This firm fixed-price delivery order is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $13,389.36 by the Defense Logistics Agency (DLA) on June 2, 2025, for the supply of Nplate 250 micrograms vials. The contract represents a firm fixed-price delivery order with an ultimate completion date of June 24, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $6,694.68 by the Defense Logistics Agency on July 29, 2025, for the supply of Nplate 250 microgram vials. The award carries an ultimate completion date of August 19, 2025, and was issued without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $3,366.20 by the Defense Logistics Agency on September 2, 2025, for the supply of Nplate 125 microgram vials. This delivery order is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and extending through November 2026. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $3,347.34 by the Defense Logistics Agency on July 31, 2025, for the supply of Nplate 250 microgram vials. The delivery order carries an ultimate completion date of August 21, 2025, and requires performance at the contractor's Park Ridge, Illinois facility. This award was issued without a set-aside designation, allowing DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on September 10, 2025, for the supply of Nplate 250 microgram vials. The contract, valued at $16,736.70, carries a firm fixed-price structure with an ultimate completion date of October 1, 2025. This delivery order was issued without a set-aside designation and is funded through the Defense Logistics Agency's Medical Supply Chain division, reflecting...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,673.67 to DMS Pharmaceutical Group Inc. for 250 microgram vials of Nplate on August 6, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order does not utilize a set-aside designation and will be performed in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois, serves as the prime contractor with no identified...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $33.5K for 500 microgram vials of Nplate by the Defense Logistics Agency's Medical Supply Chain. The award, issued on September 9, 2025, is a firm fixed-price delivery order with an ultimate completion date of September 30, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB25FX2DZDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,366.20 by the Defense Logistics Agency (DLA) on September 2, 2025, for the supply of Nplate 125 microgram vials. This firm fixed-price delivery order, which carries an ultimate completion date of September 23, 2025, is issued without a set-aside designation and represents a continuation of the company's substantial partnership with DLA. The award leverages DMS Pharmaceutical Group's position as a critical supplier within the federal pharmaceutical supply chain, building upon its existing single-award Indefinite Delivery Contract with DLA valued at $499,999,999 through November 2026 under the SPE2DB program. This delivery order exemplifies the operational structure of DLA's pharmaceutical procurement strategy, wherein the agency issues firm fixed-price orders for specific pharmaceutical products needed to support Department of Defense healthcare facilities. Nplate (romiplostim) is a thrombopoietic agent used in the treatment of immune thrombocytopenia, reflecting DMS Pharmaceutical Group's ongoing role in distributing specialty medications and biologics to military health facilities. The company's consistent success in securing federal pharmaceutical contracts without set-aside designations demonstrates its competitive strength in the government procurement market, positioning it as a reliable source for both routine and specialized pharmaceutical products across the military healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/2/25 |